Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2005 1
2006 1
2007 1
2008 1
2009 2
2010 1
2011 3
2013 1
2014 4
2015 2
2016 3
2017 4
2018 2
2019 2
2020 3
2022 5
2023 2
2024 5
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.
Jonasova A, Sotakova S, Belohlavkova P, Minarik L, Stopka T, Jonas JJ, Aghova T, Zemanova Z. Jonasova A, et al. Among authors: stopka t. Front Oncol. 2024 Oct 2;14:1398331. doi: 10.3389/fonc.2024.1398331. eCollection 2024. Front Oncol. 2024. PMID: 39416466 Free PMC article.
Role of epigenetics in chronic myeloid leukemia.
Machova Polakova K, Koblihova J, Stopka T. Machova Polakova K, et al. Among authors: stopka t. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36. doi: 10.1007/s11899-012-0152-z. Curr Hematol Malig Rep. 2013. PMID: 23296408 Free PMC article. Review.
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Jungova A, Stork M, Spicka I, Radocha J, Minarik J, Pavlicek P, Mihalyova J, Pour L, Straub J, Maisnar V, Pika T, Dekojova T, Soukup J, Popkova T, Mensikova K, Sedlák F, Pospiskova J, Boichuk I, Krhovska P, Stopka T, Jindra P, Jelínek T, Knechtová Z, Capounova V, Latal V, Muronova L, Heindorfer A, Ullrychova J, Sykora M, Kessler P, Hajek R. Jungova A, et al. Among authors: stopka t. Clin Lymphoma Myeloma Leuk. 2026 Apr;26(4):e470-e482. doi: 10.1016/j.clml.2025.10.022. Epub 2025 Nov 2. Clin Lymphoma Myeloma Leuk. 2026. PMID: 41339214
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.
Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Minařík L, et al. Among authors: stopka t. Cells. 2022 Jan 11;11(2):223. doi: 10.3390/cells11020223. Cells. 2022. PMID: 35053339 Free PMC article.
50 results